Identification

Name
Lisinopril
Accession Number
DB00722  (APRD00560)
Type
Small Molecule
Groups
Approved, Investigational
Description

Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure
Thumb
Synonyms
  • (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
  • [N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
  • Lisinopril
  • Lisinopril anhydrous
  • Lisinoprilum
Product Ingredients
IngredientUNIICASInChI Key
Lisinopril dihydrateE7199S1YWR83915-83-7CZRQXSDBMCMPNJ-ZUIPZQNBSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LisinoprilTablet10 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Act LisinoprilTablet5 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Act LisinoprilTablet20 mgOralActavis Pharma Company2007-10-17Not applicableCanada
LisinoprilTablet10 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
LisinoprilTablet20 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
LisinoprilTablet5 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
LisinoprilTablet40 mgOralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
LisinoprilTablet10 mgOralMeliapharm Inc2008-03-122014-06-25Canada
LisinoprilTablet20 mgOralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
LisinoprilTablet5 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lisinopril Tablet (type P) - 10mgTablet10 mgOralApotex Corporation1996-10-302001-08-02Canada
Apo-lisinopril Tablet (type P) - 20mgTablet20 mgOralApotex Corporation1996-10-302001-08-02Canada
Apo-lisinopril Tablet (type P) - 40mgTablet40 mgOralApotex Corporation1996-12-302001-08-02Canada
Apo-lisinopril Tablet (type P) - 5mgTablet5 mgOralApotex Corporation1996-10-302001-08-02Canada
Apo-lisinopril Tablet 10 mgTablet10 mgOralApotex Corporation1996-10-30Not applicableCanada
Apo-lisinopril Tablet 20 mgTablet20 mgOralApotex Corporation1996-10-30Not applicableCanada
Apo-lisinopril Tablet 40 mgTablet40 mgOralApotex Corporation1996-10-30Not applicableCanada
Apo-lisinopril Tablet 5 mgTablet5 mgOralApotex Corporation1996-10-30Not applicableCanada
Auro-lisinoprilTablet5 mgOralAuro Pharma Inc2013-02-12Not applicableCanada
Auro-lisinoprilTablet20 mgOralAuro Pharma Inc2013-02-12Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-lisinopril/hctzLisinopril (10 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2007-09-05Not applicableCanada
Apo-lisinopril/hctzLisinopril (20 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2007-11-21Not applicableCanada
Apo-lisinopril/hctzLisinopril (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2007-11-21Not applicableCanada
Ava-lisinopril HctLisinopril (20 mg) + Hydrochlorothiazide (25 mg)TabletOralAvanstra Inc2011-08-182014-08-21Canada
Ava-lisinopril HctLisinopril (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAvanstra Inc2011-08-182014-08-21Canada
Ava-lisinopril HctLisinopril (10 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAvanstra Inc2011-08-182014-08-21Canada
Lisinopril and HCTZLisinopril (20 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralNorthwind Pharmaceuticals2014-07-10Not applicableUs68180 0520 02 nlmimage10 16088b04
Lisinopril and HydrochlorothiazideLisinopril (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2009-06-23Not applicableUs
Lisinopril and HydrochlorothiazideLisinopril (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-09-13Not applicableUs00172 5034 60 nlmimage10 052d0288
Lisinopril and HydrochlorothiazideLisinopril (20 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralA S Medication Solutions2006-04-102017-06-20Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
LytensoprilLisinopril + L-ArginineKitPhysician Therapeutics Llc2011-07-07Not applicableUs
Lytensopril-90Lisinopril + L-ArginineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
International/Other Brands
Acebitor (GlaxoSmithKline) / Acemin (AstraZeneca) / Acerbon (AstraZeneca) / Acinopril (sanofi-aventis) / Bellisin (Ranbaxy) / Biopril (Biochem) / Dapril (Medochemie) / Fibsol (Sigma) / Fisopril (Sanofi-Aventis) / Hipril (Micro Labs) / Linopril (Klinger (Brazil)) / Lisipril (Hexal (Czech Republic), Orion (Finland)) / Noperten (Dexa (Indonesia)) / Presiten (Magnachem) / Ranolip (Ranbaxy) / Ranopril (Ranbaxy) / Rantex (Biotech) / Sinopren (Ranbaxy) / Sinopril (Eczacibasi (Russia)) / Tensopril (Merck)
Categories
UNII
7Q3P4BS2FD
CAS number
76547-98-3
Weight
Average: 405.4879
Monoisotopic: 405.226371117
Chemical Formula
C21H31N3O5
InChI Key
RLAWWYSOJDYHDC-BZSNNMDCSA-N
InChI
InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1
IUPAC Name
(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
SMILES
NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O

Pharmacology

Indication

For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or β-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.

Structured Indications
Pharmacodynamics

Lisinopril is an orally active ACE inhibitor that antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of lisinopril by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Lisinopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Lisinopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Approximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food

Volume of distribution
Not Available
Protein binding

Lisinopril does not appear to be bound to serum proteins other than ACE.

Metabolism

Does not undergo metabolism, excreted unchanged in urine.

Route of elimination

Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine.

Half life

Effective half life of accumulation following multiple dosing is 12 hours.

Clearance
  • 10 L/h [child weighting 30 kg receiving doses of 0.1 to 0.2 mg/kg]
Toxicity

Symptoms of overdose include severe hypotension, electrolyte disturbances, and renal failure. LD50= 2000 mg/kg(orally in rat). Most frequent adverse effects include headache, dizziness, cough, fatigue and diarrhea.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Lisinopril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Lisinopril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lisinopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Lisinopril.Approved, Investigational
AcebutololLisinopril may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Lisinopril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Lisinopril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Lisinopril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Lisinopril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Lisinopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Lisinopril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Lisinopril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Lisinopril.Approved
AloxiprinThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Lisinopril.Approved, Illicit, Investigational
AlprenololLisinopril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanLisinopril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lisinopril.Experimental, Investigational
AmifostineLisinopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Lisinopril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Lisinopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Lisinopril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lisinopril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Lisinopril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Lisinopril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Lisinopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Lisinopril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Lisinopril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Lisinopril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lisinopril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Lisinopril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Lisinopril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Lisinopril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Lisinopril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Lisinopril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Lisinopril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Lisinopril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Lisinopril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Lisinopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lisinopril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lisinopril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Lisinopril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Lisinopril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Lisinopril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Lisinopril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Lisinopril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lisinopril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisinopril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Lisinopril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Lisinopril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Lisinopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Lisinopril.Illicit
BarnidipineLisinopril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Lisinopril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Lisinopril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Lisinopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Lisinopril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Lisinopril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Lisinopril.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Lisinopril.Approved
BepridilLisinopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Lisinopril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Lisinopril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Lisinopril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Lisinopril.Experimental
BimatoprostLisinopril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Lisinopril.Approved
BoceprevirThe serum concentration of Lisinopril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Lisinopril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Lisinopril.Approved, Investigational
BQ-123Lisinopril may increase the hypotensive activities of BQ-123.Investigational
BretyliumLisinopril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Lisinopril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Lisinopril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lisinopril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Lisinopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Lisinopril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Lisinopril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Lisinopril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Lisinopril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lisinopril.Approved, Investigational
BupranololLisinopril may increase the hypotensive activities of Bupranolol.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Lisinopril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Lisinopril.Approved
CadralazineCadralazine may increase the hypotensive activities of Lisinopril.Experimental
CafedrineLisinopril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisinopril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Lisinopril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Lisinopril.Experimental
CaptoprilLisinopril may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Lisinopril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lisinopril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Lisinopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Lisinopril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Lisinopril.Approved
CarvedilolLisinopril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Lisinopril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lisinopril.Approved, Investigational
CeliprololLisinopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Lisinopril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Lisinopril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Lisinopril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lisinopril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Lisinopril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lisinopril.Approved
CicletanineLisinopril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilLisinopril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lisinopril.Approved, Investigational
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Lisinopril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lisinopril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Lisinopril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Lisinopril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Lisinopril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Lisinopril.Approved
CloranololLisinopril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lisinopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Lisinopril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Lisinopril.Approved
CryptenamineLisinopril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Lisinopril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Lisinopril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Lisinopril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Lisinopril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Lisinopril.Approved, Investigational
DelaprilLisinopril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Lisinopril.Approved
DersalazineThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineLisinopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lisinopril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Lisinopril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lisinopril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Lisinopril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Lisinopril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Lisinopril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Diclofenamide.Approved, Investigational
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Lisinopril.Approved, Investigational
DiethylnorspermineLisinopril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lisinopril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Lisinopril.Experimental
DiflunisalThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lisinopril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Lisinopril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Lisinopril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Lisinopril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Lisinopril.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dipyridamole.Approved
DorzolamideLisinopril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Lisinopril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Lisinopril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Lisinopril.Approved, Investigational
DrospirenoneLisinopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Lisinopril.Withdrawn
DuloxetineLisinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Lisinopril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Lisinopril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Lisinopril.Investigational
EfonidipineLisinopril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
EnalaprilatLisinopril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Lisinopril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Lisinopril.Approved, Investigational
EpanololLisinopril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Lisinopril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Lisinopril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Lisinopril.Approved
EpoprostenolLisinopril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lisinopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Lisinopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Lisinopril.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Lisinopril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Lisinopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Lisinopril.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Lisinopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Lisinopril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Lisinopril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Lisinopril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lisinopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Lisinopril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Lisinopril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Lisinopril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Lisinopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Lisinopril.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Lisinopril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Lisinopril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Lisinopril.Experimental
FelodipineLisinopril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Lisinopril.Approved
FenoldopamLisinopril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Lisinopril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Lisinopril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Lisinopril.Experimental
Ferulic acidLisinopril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lisinopril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Lisinopril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Lisinopril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Lisinopril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Lisinopril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lisinopril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Lisinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Lisinopril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
GarlicThe serum concentration of Lisinopril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GuacetisalThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Lisinopril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Lisinopril.Approved
GuanazodineLisinopril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineLisinopril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Lisinopril.Approved, Investigational
GuanoclorLisinopril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLisinopril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLisinopril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lisinopril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Lisinopril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Lisinopril is combined with Heparin.Approved, Investigational
HexamethoniumLisinopril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Lisinopril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Lisinopril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Lisinopril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Lisinopril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Lisinopril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Lisinopril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Lisinopril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lisinopril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Lisinopril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Lisinopril.Approved, Investigational
ImidaprilLisinopril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Lisinopril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Lisinopril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Lisinopril.Approved
IndenololLisinopril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Lisinopril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lisinopril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Lisinopril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Lisinopril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Lisinopril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Lisinopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Lisinopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lisinopril.Approved, Investigational
IronIron can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Lisinopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lisinopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lisinopril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lisinopril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Lisinopril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Lisinopril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisinopril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lisinopril.Approved
LabetalolLabetalol may increase the hypotensive activities of Lisinopril.Approved
LacidipineLisinopril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Lisinopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Lisinopril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Lisinopril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Lisinopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lisinopril.Approved, Investigational
LevodopaLisinopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Lisinopril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Lisinopril.Approved
LinsidomineLisinopril may increase the hypotensive activities of Linsidomine.Experimental
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Lisinopril.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Lisinopril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Lisinopril.Experimental
LofexidineLisinopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Lisinopril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Lisinopril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Lisinopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lisinopril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Lisinopril.Approved, Investigational
MacitentanLisinopril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lisinopril.Approved
ManidipineLisinopril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lisinopril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Lisinopril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Lisinopril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisinopril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Lisinopril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Lisinopril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lisinopril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Lisinopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lisinopril.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Lisinopril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Lisinopril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Lisinopril.Approved
MethoserpidineLisinopril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Lisinopril.Approved
Methyl salicylateThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaLisinopril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Lisinopril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Lisinopril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Lisinopril.Approved
MetipranololLisinopril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Lisinopril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Lisinopril.Approved, Investigational
MetyrosineLisinopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilLisinopril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Lisinopril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Lisinopril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Lisinopril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Lisinopril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lisinopril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Lisinopril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Lisinopril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Lisinopril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Lisinopril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lisinopril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Lisinopril.Approved, Investigational
MuzolimineLisinopril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lisinopril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisinopril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Lisinopril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Lisinopril.Approved
NadololLisinopril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Lisinopril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lisinopril.Approved
NaftopidilLisinopril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Lisinopril.Approved, Vet Approved
NebivololLisinopril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Lisinopril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Lisinopril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Lisinopril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Lisinopril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Lisinopril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Lisinopril.Approved
NiguldipineLisinopril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineLisinopril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lisinopril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Lisinopril.Approved
NitrendipineLisinopril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Lisinopril.Approved
NitroaspirinThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Lisinopril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Lisinopril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Lisinopril.Approved
ObinutuzumabLisinopril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Lisinopril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lisinopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lisinopril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lisinopril.Approved
OmapatrilatLisinopril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Lisinopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Lisinopril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisinopril.Approved
OxprenololLisinopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisinopril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lisinopril.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Lisinopril.Approved
PargylinePargyline may increase the hypotensive activities of Lisinopril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Lisinopril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Patent Blue.Approved
PenbutololLisinopril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational, Vet Approved
PentoliniumLisinopril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lisinopril.Approved, Investigational
PerindoprilLisinopril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Lisinopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Lisinopril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
PhenoxybenzamineLisinopril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lisinopril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Lisinopril.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lisinopril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lisinopril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Lisinopril.Approved
PindololLisinopril may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lisinopril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Lisinopril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lisinopril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Lisinopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lisinopril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Lisinopril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Lisinopril.Withdrawn
Platelet Activating FactorLisinopril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Lisinopril.Approved
PotassiumPotassium may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Lisinopril.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Lisinopril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Lisinopril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Lisinopril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Lisinopril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Lisinopril.Approved
PregabalinThe risk or severity of angioedema can be increased when Lisinopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Lisinopril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Lisinopril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Lisinopril.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lisinopril.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Lisinopril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Lisinopril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Lisinopril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Lisinopril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Lisinopril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.Approved
QuinaprilLisinopril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Lisinopril.Approved
QuinineQuinine may increase the hypotensive activities of Lisinopril.Approved
RamiprilRamipril may increase the hypotensive activities of Lisinopril.Approved
RasagilineRasagiline may increase the hypotensive activities of Lisinopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lisinopril.Approved
RemikirenRemikiren may increase the hypotensive activities of Lisinopril.Approved
RescinnamineLisinopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Lisinopril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lisinopril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Lisinopril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Lisinopril.Approved
RisperidoneLisinopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabLisinopril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Lisinopril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lisinopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Lisinopril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Lisinopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Lisinopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lisinopril.Approved
Salicylic acidThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Lisinopril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lisinopril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lisinopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Lisinopril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Lisinopril.Approved, Investigational, Vet Approved
SelexipagLisinopril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Lisinopril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Lisinopril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Lisinopril.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lisinopril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Lisinopril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lisinopril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Lisinopril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Lisinopril.Approved, Investigational
SitaxentanLisinopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Lisinopril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphateLisinopril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.Approved
SpiraprilLisinopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Lisinopril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Lisinopril.Investigational
St. John's WortThe metabolism of Lisinopril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Lisinopril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lisinopril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lisinopril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Lisinopril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Lisinopril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Lisinopril.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Lisinopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Lisinopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Lisinopril.Approved, Investigational
TalinololLisinopril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Lisinopril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Lisinopril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lisinopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisinopril.Approved, Investigational
TemocaprilLisinopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Lisinopril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Lisinopril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Lisinopril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Lisinopril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Lisinopril.Approved
TerlipressinLisinopril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineLisinopril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lisinopril.Approved, Investigational, Withdrawn
TheodrenalineLisinopril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Lisinopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Lisinopril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lisinopril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Lisinopril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Lisinopril.Approved
TiboloneLisinopril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenLisinopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Lisinopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Lisinopril.Investigational
TipranavirThe serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Lisinopril.Approved, Investigational
TolazolineLisinopril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Lisinopril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Lisinopril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lisinopril.Approved
TolonidineLisinopril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Lisinopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Lisinopril.Approved
TorasemideTorasemide may increase the hypotensive activities of Lisinopril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Lisinopril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Lisinopril.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Lisinopril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Lisinopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Lisinopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Lisinopril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Lisinopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Lisinopril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Lisinopril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Lisinopril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Lisinopril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Lisinopril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Lisinopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Lisinopril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Lisinopril.Investigational
Trolamine salicylateThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Lisinopril.Approved, Investigational
UnoprostoneLisinopril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Lisinopril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Lisinopril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Lisinopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Lisinopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Lisinopril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Lisinopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Lisinopril.Approved, Investigational
VincamineLisinopril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineLisinopril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideLisinopril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineLisinopril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Lisinopril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Lisinopril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Lisinopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Lisinopril.Approved, Investigational, Withdrawn
ZofenoprilLisinopril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lisinopril.Withdrawn
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of lisinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of lisinopril.
  • Lisinopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Take without regard to meals.

References

Synthesis Reference

Vincenzo Cannata, Valeriano Merli, Stefano Saguatti, "Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril." U.S. Patent US6166217, issued September, 1972.

US6166217
General References
  1. Abdelmalek MF, Douglas DD: Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema. Dig Dis Sci. 1997 Apr;42(4):847-50. [PubMed:9125659]
  2. Hasslacher C: Influence of the ACE inhibitor lisinopril on blood pressure, metabolism, and renal function parameter in hypertensive type II diabetic patients: a postmarketing surveillance study. J Diabetes Complications. 1996 May-Jun;10(3):136-8. [PubMed:8807458]
  3. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P: Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009 Sep;32(9):1684-8. doi: 10.2337/dc09-0429. Epub 2009 Jun 5. [PubMed:19502542]
  4. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826]
External Links
Human Metabolome Database
HMDB0001938
KEGG Drug
D00362
PubChem Compound
5362119
PubChem Substance
46504893
ChemSpider
4514933
BindingDB
50367879
ChEBI
43755
ChEMBL
CHEMBL1237
Therapeutic Targets Database
DAP000587
PharmGKB
PA450242
HET
LPR
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Lisinopril
ATC Codes
C09AA03 — LisinoprilC09BB03 — Lisinopril and amlodipineC10BX07 — Rosuvastatin, amlodipine and lisinoprilC09BA03 — Lisinopril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
PDB Entries
1j36 / 1o86 / 2c6n / 2x91
FDA label
Download (267 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableTo Determine Bioequivalence Under Fed Conditions1
1CompletedNot AvailableType 2 Diabetes Mellitus1
1CompletedBasic ScienceGastroparesis1
1CompletedOtherHealthy Volunteers1
1CompletedPreventionHigh Blood Pressure (Hypertension)1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers2
1CompletedTreatmentFasting2
1CompletedTreatmentFed2
1CompletedTreatmentHigh Blood Pressure (Hypertension)5
1CompletedTreatmentStrokes1
1CompletedTreatmentType 2 Diabetes Mellitus1
1RecruitingTreatmentHypertension, Resistant to Conventional Therapy1
1, 2CompletedTreatmentPre-Hypertension1
2Active Not RecruitingSupportive CareCancer, Breast / Cardiac Toxicity1
2CompletedTreatmentAging / Cognitive Impairments / High Blood Pressure (Hypertension)1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentHypertension,Essential1
2CompletedTreatmentOligozoospermia1
2Not Yet RecruitingPreventionPacemakers, Heart Failure1
2Not Yet RecruitingTreatmentAlbuminuria / Genetic Predisposition / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Kidney Diseases1
2RecruitingTreatmentAcute Coronary Syndromes (ACS) / Arterial Hypertension1
2RecruitingTreatmentExtracapillary Glomerulonephritis1
2TerminatedTreatmentHigh Blood Pressure (Hypertension) / Unspecified Adult Solid Tumor, Protocol Specific1
2, 3Enrolling by InvitationTreatmentBecker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD) / Limb Girdle Muscular Dystrophy1
3Active Not RecruitingPreventionHigh Blood Pressure (Hypertension) / Mild Cognitive Impairment (MCI)1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Myocardial Infarction (MI) / Myocardial Ischemia1
3CompletedPreventionDiabetic Nephropathies1
3CompletedTreatmentHigh Blood Pressure (Hypertension)3
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Obesity, Abdominal1
3CompletedTreatmentKidney, Polycystic2
3CompletedTreatmentLeft Ventricular Hypertrophy1
3TerminatedTreatmentHeart Failure, Congestive and Microalbuminuria / High Blood Pressure (Hypertension) / Microalbuminuria1
3TerminatedTreatmentHemodialysis-dependent patients / High Blood Pressure (Hypertension) / Left Ventricular Hypertrophy1
3TerminatedTreatmentKidney Diseases / Renal Dysfunction / Type 2 Diabetes Mellitus1
3Unknown StatusTreatmentCardiovascular Disease (CVD)1
3WithdrawnPreventionHyperoxaluria1
4CompletedPreventionPerioperative Hypertension1
4CompletedTreatmentDiabetic Nephropathies1
4CompletedTreatmentDiabetic Nephropathies / High Blood Pressure (Hypertension)1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHigh Blood Pressure (Hypertension)3
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
4CompletedTreatmentStage 2 Diastolic Hypertension1
4Not Yet RecruitingPreventionCardiomyopathy Due to Drug / Heart Failure, Systolic1
4Not Yet RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4RecruitingTreatmentPediatric Hypertension1
4RecruitingTreatmentProteinuria / Renal Insufficiency,Chronic1
4SuspendedPreventionCardiovascular Disease (CVD) / Osteoarthritis (OA)1
4TerminatedPreventionNeurological Dysphagia / Pneumonia1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4Unknown StatusTreatmentHypertension,Essential / Secondary Hypertension1
Not AvailableActive Not RecruitingSupportive CareDyspnea / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC)1
Not AvailableActive Not RecruitingTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / High Blood Pressure (Hypertension) / Myocardial Infarction (MI)1
Not AvailableCompletedNot AvailableDiabetes Complications / Diabetes, Diabetes Mellitus Type 1 / Eye Diseases / Retinopathy, Diabetic1
Not AvailableCompletedDiagnosticArterial Hypertension1
Not AvailableCompletedOtherHyperparathyroidism1
Not AvailableCompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Cerebral Arteriosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / High Blood Pressure (Hypertension)1
Not AvailableCompletedPreventionBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
Not AvailableCompletedPreventionCardiovascular Disease Risk / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedPreventionDiabetes, Diabetes Mellitus Type 1 / Diabetic Nephropathies1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Pre-Diabetic1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD) / Cerebrovascular Diseases / Peripheral Arterial Disease (PAD)1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentDuchenne's Muscular Dystrophy (DMD) / Prophylaxis of cardiomyopathy1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Hypertension Treatment / Hypertension, Grade 1 / N of 1 Study Design1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Plasma Renin Activity1
Not AvailableCompletedTreatmentHypertension,Essential1
Not AvailableTerminatedPreventionThoracic Pain1
Not AvailableTerminatedTreatmentType 2 Diabetes Mellitus1
Not AvailableWithdrawnTreatmentDiastolic Heart Failure1
Not AvailableWithdrawnTreatmentHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lek pharmaceuticals d d
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Ranbaxy pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Wockhardt ltd
  • Merck research laboratories div merck co inc
  • Astrazeneca uk ltd
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • AstraZeneca Inc.
  • Aurobindo Pharma Ltd.
  • Blu Pharmaceuticals LLC
  • Bryant Ranch Prepack
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Golden State Medical Supply Inc.
  • Greenstone LLC
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • International Laboratories Inc.
  • IPR Pharmaceuticals Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Lek Pharmaceuticals Inc.
  • Liberty Pharmaceuticals
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medvantx Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neighborcare Repackaging Inc.
  • Novartis AG
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Professional Co.
  • Promex Medical Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Stat Scripts LLC
  • Talbert Medical Management Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
TabletOral40 mg
TabletOral5 mg
TabletOral10 mg/301
TabletOral10 mg/1
TabletOral10 1/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
TabletOral
Kit
TabletOral10 mg
TabletOral2.5 mg
TabletOral20 mg
SolutionOral1 mg/mL
Prices
Unit descriptionCostUnit
Prinivil 90 20 mg tablet Bottle111.71USD bottle
Prinzide 30 20-12.5 mg tablet Bottle45.99USD bottle
Prinivil 30 2.5 mg tablet Bottle22.48USD bottle
Lisinopril 100% powder21.6USD g
Zestril 40 mg tablet2.53USD tablet
Zestril 30 mg tablet2.41USD tablet
Prinivil 40 mg tablet2.23USD tablet
Zestoretic 20-25 mg tablet2.01USD tablet
Zestoretic 20-12.5 mg tablet2.0USD tablet
Prinzide 20-25 mg tablet1.98USD tablet
Zestoretic 10-12.5 mg tablet1.89USD tablet
Zestoretic 10-12.5 tablet1.75USD tablet
Lisinopril 30 mg tablet1.53USD tablet
Lisinopril 40 mg tablet1.44USD tablet
Prinzide 20-12.5 mg tablet1.38USD tablet
Prinzide 10-12.5 mg tablet1.37USD tablet
Zestril 20 mg tablet1.37USD tablet
Zestril 10 mg tablet1.33USD tablet
Zestoretic 20-25 tablet1.28USD tablet
Zestril 5 mg tablet1.28USD tablet
Zestoretic 20-12.5 tablet1.26USD tablet
Lisinopril 20 mg tablet1.09USD tablet
Prinivil 20 mg tablet1.05USD tablet
Zestril 2.5 mg tablet1.04USD tablet
Lisinopril 10 mg tablet1.01USD tablet
Prinivil 10 mg tablet1.01USD tablet
Lisinopril 5 mg tablet0.99USD tablet
Prinivil 5 mg tablet0.96USD tablet
Apo-Lisinopril 20 mg Tablet0.71USD tablet
Co Lisinopril 20 mg Tablet0.71USD tablet
Mylan-Lisinopril 20 mg Tablet0.71USD tablet
Novo-Lisinopril (Type P) 20 mg Tablet0.71USD tablet
Novo-Lisinopril (Type Z) 20 mg Tablet0.71USD tablet
Pms-Lisinopril 20 mg Tablet0.71USD tablet
Ran-Lisinopril 20 mg Tablet0.71USD tablet
Ratio-Lisinopril P 20 mg Tablet0.71USD tablet
Ratio-Lisinopril Z 20 mg Tablet0.71USD tablet
Sandoz Lisinopril 20 mg Tablet0.71USD tablet
Lisinopril 2.5 mg tablet0.65USD tablet
Apo-Lisinopril 10 mg Tablet0.59USD tablet
Co Lisinopril 10 mg Tablet0.59USD tablet
Mylan-Lisinopril 10 mg Tablet0.59USD tablet
Novo-Lisinopril (Type P) 10 mg Tablet0.59USD tablet
Novo-Lisinopril (Type Z) 10 mg Tablet0.59USD tablet
Pms-Lisinopril 10 mg Tablet0.59USD tablet
Ran-Lisinopril 10 mg Tablet0.59USD tablet
Ratio-Lisinopril P 10 mg Tablet0.59USD tablet
Ratio-Lisinopril Z 10 mg Tablet0.59USD tablet
Sandoz Lisinopril 10 mg Tablet0.59USD tablet
Apo-Lisinopril 5 mg Tablet0.49USD tablet
Co Lisinopril 5 mg Tablet0.49USD tablet
Mylan-Lisinopril 5 mg Tablet0.49USD tablet
Novo-Lisinopril (Type P) 5 mg Tablet0.49USD tablet
Novo-Lisinopril (Type Z) 5 mg Tablet0.49USD tablet
Pms-Lisinopril 5 mg Tablet0.49USD tablet
Ran-Lisinopril 5 mg Tablet0.49USD tablet
Ratio-Lisinopril P 5 mg Tablet0.49USD tablet
Ratio-Lisinopril Z 5 mg Tablet0.49USD tablet
Sandoz Lisinopril 5 mg Tablet0.49USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9463183No2015-11-062035-11-06Us
US9616096No2015-11-062035-11-06Us
US9814751No2015-11-062035-11-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility9.7E+004 mg/LMERCK INDEX (1996)
logP-1.01MERCK INDEX (1996); pH 7
pKa2.5 (at 25 °C)MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.216 mg/mLALOGPS
logP-1.2ALOGPS
logP-3.1ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.17ChemAxon
pKa (Strongest Basic)10.21ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area132.96 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity107.37 m3·mol-1ChemAxon
Polarizability43.5 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6426
Blood Brain Barrier-0.8815
Caco-2 permeable-0.7605
P-glycoprotein substrateSubstrate0.6515
P-glycoprotein inhibitor INon-inhibitor0.9512
P-glycoprotein inhibitor IINon-inhibitor0.969
Renal organic cation transporterNon-inhibitor0.8574
CYP450 2C9 substrateNon-substrate0.8793
CYP450 2D6 substrateNon-substrate0.7622
CYP450 3A4 substrateNon-substrate0.725
CYP450 1A2 substrateNon-inhibitor0.8999
CYP450 2C9 inhibitorNon-inhibitor0.9708
CYP450 2D6 inhibitorNon-inhibitor0.9653
CYP450 2C19 inhibitorNon-inhibitor0.8266
CYP450 3A4 inhibitorNon-inhibitor0.907
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9821
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9389
BiodegradationNot ready biodegradable0.6844
Rat acute toxicity1.8723 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9641
hERG inhibition (predictor II)Non-inhibitor0.8708
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0a4r-0194100000-d9a47a283478b88bb101
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-001i-9040000000-8d6d4ae6ba18da11e336
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-001i-9000000000-77e20f7eb799eea58ab0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Benzene and substituted derivatives / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides
show 9 more
Substituents
Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidine
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dipeptide (CHEBI:43755)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]
  5. Tellez-Sanz R, Garcia-Fuentes L, Baron C: Calorimetric analysis of lisinopril binding to angiotensin I-converting enzyme. FEBS Lett. 1998 Feb 13;423(1):75-80. [PubMed:9506845]

Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:49